Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib and 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors
NCT03611595Phase 1Completed
- Start
- Aug 2018
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cabozantinib in solid tumor. Primary endpoint: Maximum Tolerated Dose at 12 months. Started Aug 2018; status: completed.
02
Drugs
cabozantinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03611595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03611595.